UNSPSC 51191574: Chlorothiazide sodium

This classification denotes a thiazide diuretic with the molecular formula C7H4ClN3O4S2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SN86FG7N2K, chemically known as 6-chloro-2h-1,2,4-benzothiadiazine-7-sulfonamide, 1,1-dioxide, monosodium salt but more generally known as chlorothiazide sodium, which bears US NIH Compound Identifier 23490. European Medicines Agency schedules Chlorothiazide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21994.

UNSPSC 51191574 Chlorothiazide sodium is a Commodity code covering pharmaceutical and chemical supply acquisitions by state and local government agencies. Recent state and local solicitations under this code show activity centered on chemical supply for municipal water treatment and multi-source pharmaceutical procurement for state and local healthcare facilities. The City of Meriden, Connecticut and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the issuing bodies active in this space. Scope spans both industrial chemical commodities (sodium bisulfite for water pollution control) and pharmaceutical products (generic multi-source drugs and over-the-counter items distributed to state and local facilities). Buyers typically evaluate pricing on a unit-cost basis and require vendors to maintain specified insurance coverage, comply with manufacturing standards (cGMP, FDA requirements, Drug Supply Chain Security Act compliance), and submit detailed product specifications including National Drug Codes, SKUs, and packaging configurations.

Activity is concentrated in the Upper Midwest and Northeast, with recent opportunities posted from Connecticut and Minnesota. The City of Meriden issued an IFB for sodium bisulfite with a response deadline of July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000 and performance bonds. MMCAP issued an RFP (solicitation S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, covering multiple participating state and local facilities including Oregon. The MMCAP contract requires vendors to maintain commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with awarded vendors obligated to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and pay a 3 percent administrative fee on all purchases.